Constantine Kroustos, MD
Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1750404984
Payments from drug & device makers
Across 774 payments — averaging $68.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$19K
- Lilly USA, LLC$12K
- Boehringer Ingelheim$10K
- Dexcom, Inc.$1K
- Xeris Pharmaceuticals, Inc.$1K
- Novo Nordisk$1K
- plus $8K from 53 others
What the payments were for
- Consulting fees$2,9256%
- Speaking & faculty fees$34,23365%
- Travel & lodging$2,3184%
- Food & beverage$13,44425%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$20,786
- INVOKANA$18,720
- FARXIGA$181
- GVOKE HYPOPEN$135
- Ozempic$121
- DEXCOM G6 TRANSMITTER$101
How this compares
$52,953 in reported general payments places this provider in the 80th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 143 | $242,028 |
| Humalog Kwikpen U-200Insulin Lispro | 46 | $146,949 |
| TrulicityDulaglutide | 71 | $128,738 |
| JardianceEmpagliflozin | 79 | $105,937 |
| MounjaroTirzepatide | 65 | $86,623 |
| FarxigaDapagliflozin Propanediol | 51 | $65,377 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $60,944 |
| JanuviaSitagliptin Phosphate | 48 | $51,886 |
| ProliaDenosumab | 25 | $43,490 |
| Novolog FlexpenInsulin Aspart | 66 | $37,598 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $36,640 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 29 | $34,187 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 23 | $30,297 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $30,286 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $28,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,012 | $249,434159 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $12,379 | $225,805164 claims |
| Boehringer IngelheimJardiance, Glyxambi | $10,333 | $127,60594 claims |
| MerckJanuvia, Janumet Xr | $120 | $65,72870 claims |
| AstraZenecaFarxiga | $392 | $65,37751 claims |
| AmgenProlia | $857 | $43,49025 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $405 | $32,64734 claims |
| AbbVieSynthroid | $250 | $10,907135 claims |
| IBSA Pharma Inc.Tirosint | $164 | $6,12321 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $190 | $2,630303 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Columbus
- Elena ChristofidesColumbus$3.5M
- Steven IngColumbus$1.9M
- Kathleen DunganColumbus$1.4M
- Kyaw SoeColumbus$1.3M
- Samuel AndersonColumbus$556K
- Kathleen WyneColumbus$510K
- Luma GhalibColumbus$180K
- Ravi DhawaleColumbus$175K
- Lawrence KirschnerColumbus$142K
- Laura RyanColumbus$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.